3 completed, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow ALXN2060: new trials by email Literature Review of ALXN2060 trials Research Report on ALXN2060
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Acoramidis (AG10) - Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Not yet recruiting | Eidos Therapeutics, a BridgeBio company | 250 | 2026-11-01 | 2026-08-11 |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant Acoramidis, Placebo oral tablet - Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Recruiting | Eidos Therapeutics, a BridgeBio company | 587 | 2025-05-12 | 2026-08-04 |
| Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants Acoramidis - Healthy | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 18 | 2021-05-30 | 2026-03-06 |
| A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM ALXN2060 - Symptomatic Transthyretin Amyloid Cardiomyopathy | Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 25 | 2020-11-13 | 2026-06-10 |
| Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy acoramidis, Placebo Oral Tablet - Amyloidosis, Amyloid Cardiomyopathy | Phase 3 | Completed | Eidos Therapeutics, a BridgeBio company | 632 | 2019-03-19 | 2024-06-27 |
Alzheimer Disease (3) · Amyloid Neuropathies, Familial (3) · Amyloidosis (3) · Amyloidosis, Hereditary, Transthyretin-Related (3) · Cardiomyopathies (3) · Heart Diseases (3) · Polyneuropathies (2) · Amyloidosis, Familial (1)
Eidos Therapeutics, a BridgeBio company (3) · Alexion Pharmaceuticals, Inc. (2)
United States (3) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · Denmark (2) · Greece (2) · Ireland (2) · Italy (2) · Japan (2) · Netherlands (2) · Portugal (2) · South Korea (2) · Spain (2) · United Kingdom (2)
PMID 33725199, PMID 38197816, PMID 39878480, PMID 40074465, PMID 40398971, PMID 40750720, PMID 41205147, PMID 41384357, PMID 42110872, PMID 42216490, PMID 42307157, PMID 42389794, PMID 42525404, PMID 42554365, PMID 42622768, PMID 42669902
2018 (1)